# Safety and Efficacy of Avalglucosidase Alfa in Patients With Non-classic Pompe Disease Aged ≥ 5 Years

> **NCT07652814** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Iris Plug** · enrollment: 6 (estimated)

## Conditions studied

- Glycogen Storage Disease Type II Late Onset
- Pompe Disease (Late-onset)
- Pompe Disease Late-Onset
- Pompe's Disease Juvenile Onset
- Pompe Disease

## Interventions

- **DRUG:** Avalglucosidase Alfa

## Key facts

- **NCT ID:** NCT07652814
- **Lead sponsor:** Iris Plug
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-10-13
- **Primary completion:** 2028-03-09
- **Final completion:** 2028-03-09
- **Target enrollment:** 6 (ESTIMATED)
- **Last updated:** 2026-06-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07652814

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07652814, "Safety and Efficacy of Avalglucosidase Alfa in Patients With Non-classic Pompe Disease Aged ≥ 5 Years". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07652814. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*